Northwestern University

Running trials

• Not yet recruiting

  Preoperative Durvalumab, Cisplatin, Gemcitabine With or Without Futibatinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, OPTIC Trial

  NCT07639528· Phase 2· Source

• Not yet recruiting

  Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

  NCT07594548· Phase 1· Source

• Not yet recruiting

  Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT Carcinoma

  NCT07863765· Phase 2· Source

• Not yet recruiting

  A MOST Framework Trial Evaluating the MOst effectiVe Exercise Types for Blood Pressure Control

  NCT07915752· Source

• Not yet recruiting

  Using an Artificial Intelligence Software Tool (iSeg) During Radiation Treatment Planning for Patients With Lung Tumors

  NCT07898241· Source

• Not yet recruiting

  The AYA Oncology Self-care Movement

  NCT07724652· Source

• Not yet recruiting

  Fit2ThriveMB: Optimization of a Physical Activity Promotion Intervention for Metastatic Breast Cancer Patients

  NCT07840599· Source

• Not yet recruiting

  A Phase I First-in-human Trial of Bvax (B-cell Vaccination) in Addition to Standard of Care Chemoradiotherapy for Newly Diagnosed Glioblastoma

  NCT07422896· Phase 1· Source

• Not yet recruiting

  Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis

  NCT07674745· Phase 2· Source

• Not yet recruiting

  COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"

  NCT07281027· Phase 3· Source

• Recruiting

  Liver Transplantation From Donors With HIV: Impact on Opportunistic Infections, Cancer, and Long-Term Outcomes (Expanding HOPE Liver)

  NCT07665372· Source

• Not yet recruiting

  A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer

  NCT07349641· Phase 2· Source

• Recruiting

  SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial

  NCT07748611· Phase 2· Source

• Not yet recruiting

  Testing the SurVaxM Vaccine for Lung Cancer Prevention

  NCT07169617· Phase 2· Source

• Not yet recruiting

  Gestational Hypertension and Preeclampsia Blood Pressure (BP) Treatment Goals Less Than 140/90 vs. Less Than 160/110 mmHg: The GOALPOST Trial

  NCT07746271· Phase 3· Source

• Recruiting

  Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

  NCT06917911· Phase 2· Source

• Not yet recruiting

  Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis

  NCT07520110· Phase 3· Source

• Enrolling by invitation

  The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal Foralumab

  NCT07688239· Phase 2· Source

• Not yet recruiting

  Stroke Training to Advance Balance During Locomotor Experiences (STABLE) Trial

  NCT07802470· Source

• Recruiting

  BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion

  NCT07594626· Phase 1/2· Source

• Recruiting

  Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive Cisplatin

  NCT07441681· Phase 3· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Source

• Recruiting

  Pridopidine Phase 3 Study in Huntington's Disease

  NCT07609108· Phase 3· Source

• Recruiting

  The REACH-OUT Trial

  NCT07540143· Source

• Recruiting

  A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

  NCT07595549· Phase 3· Source

• Recruiting

  MINT Conditioning to Improve Gait

  NCT07041775· Source

• Recruiting

  Defining the Ablative Dose for Y-90 TARE

  NCT07586046· Phase 2· Source

• Recruiting

  PREACTIVE: Preconditioning Exercise Intervention to Improve Symptoms and Quality of Life in Comorbid Atrial Fibrillation and HFpEF

  NCT07324772· Source

• Recruiting

  Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System

  NCT07579702· Source

• Recruiting

  Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)

  NCT07296744· Source

• Recruiting

  Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes

  NCT07521475· Source

• Recruiting

  Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

  NCT07321652· Phase 3· Source

• Recruiting

  Selenium Supplementation in Moderate-Severely Active Ulcerative Colitis Patients Treated With Advanced Therapies

  NCT07427017· Phase 2· Source

• Recruiting

  Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

  NCT07195734· Phase 2· Source

• Recruiting

  A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD

  NCT07285655· Phase 3· Source

• Recruiting

  Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

  NCT07068074· Phase 3· Source

• Recruiting

  A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  NCT06769698· Phase 2· Source

• Recruiting

  N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy

  NCT07261657· Early phase 1· Source

• Recruiting

  Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

  NCT07200830· Phase 3· Source

• Recruiting

  Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer

  NCT07042919· Phase 1/2· Source

• Recruiting

  LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

  NCT07415044· Phase 2· Source

• Recruiting

  A Multi Center Study Testing a New Implant for Adults With Severe Emphysema

  NCT07119229· Source

• Recruiting

  Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry Study

  NCT07676565· Source

• Recruiting

  Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

  NCT06900595· Phase 2· Source

• Recruiting

  Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD

  NCT07059091· Phase 2· Source

• Active, not recruiting

  GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes

  NCT07228117· Source

• Recruiting

  Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

  NCT07322003· Phase 3· Source

• Recruiting

  Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

  NCT07198074· Phase 3· Source

• Recruiting

  A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

  NCT07277231· Phase 3· Source

• Recruiting

  Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

  NCT07195695· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer21 recruiting
• Prostate cancer13 recruiting
• High blood pressure10 recruiting
• Stroke10 recruiting
• Head and neck cancer9 recruiting
• Pancreatic cancer9 recruiting
• Acute myeloid leukemia8 recruiting
• Bladder cancer8 recruiting
• Childhood cancers8 recruiting
• Gastric and esophageal cancer8 recruiting
• Heart failure8 recruiting
• ALS (motor neurone disease)7 recruiting
• Chronic lymphocytic leukaemia7 recruiting
• Endometrial cancer6 recruiting
• Metastatic breast cancer6 recruiting
• Ovarian cancer6 recruiting
• Sarcoma6 recruiting
• Alzheimer disease5 recruiting
• Colorectal cancer5 recruiting
• Cystic fibrosis5 recruiting
• Liver and biliary tract cancer5 recruiting
• Neuroendocrine tumours5 recruiting
• Type 1 diabetes5 recruiting
• Type 2 diabetes5 recruiting
• Atrial fibrillation4 recruiting
• Coronary artery disease4 recruiting
• Epilepsy4 recruiting
• Glioblastoma4 recruiting
• Kidney cancer4 recruiting
• Melanoma4 recruiting
• Myelodysplastic syndromes4 recruiting
• Pulmonary arterial hypertension4 recruiting
• Ulcerative colitis4 recruiting
• Acute lymphoblastic leukaemia3 recruiting
• Chronic kidney disease3 recruiting
• COPD3 recruiting
• Diffuse large B-cell lymphoma3 recruiting
• Frontotemporal dementia3 recruiting
• HIV3 recruiting
• Idiopathic pulmonary fibrosis3 recruiting
• Myeloproliferative neoplasms3 recruiting
• Obesity3 recruiting
• Parkinson disease3 recruiting
• Thyroid cancer3 recruiting
• Triple-negative breast cancer3 recruiting
• Amyloidosis2 recruiting
• Crohn's disease2 recruiting
• Follicular lymphoma2 recruiting
• Huntington's disease2 recruiting
• Rheumatoid arthritis2 recruiting
• ANCA-associated vasculitis1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Cervical cancer1 recruiting
• Depression1 recruiting
• Duchenne muscular dystrophy1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Hepatitis B1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• IgA nephropathy1 recruiting
• Mantle cell lymphoma1 recruiting
• Mesothelioma1 recruiting
• Multiple myeloma1 recruiting
• Multiple sclerosis1 recruiting
• Primary biliary cholangitis1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Tuberculosis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Withdrawn

  Implementation of AIP Services for Older Adults With AD

  NCT07361601· Source

• Completed

  SAGE LEAF 2: An Online Program to Reduce Dementia Caregiver Burden

  NCT06708182· Source

• Recruiting

  Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis

  NCT06978660· Source

• Completed

  NE3107 in Adults With Neurological Symptoms of Long COVID

  NCT06847191· Phase 2· Source

• Completed

  A Digital Therapeutic Platform for Swallowing and Drooling Problems in Parkinson's

  NCT04664634· Phase 3· Source

• Completed

  Omnipod® SmartAdjust 2.0 System Compared to the Omnipod® 5 System in Individuals With Type 1 or Type 2 Diabetes

  NCT06865989· Source

• Completed

  GYNecologic Cancer-Related COGnitive Impairment

  NCT06662435· Source

• Completed

  REVEAL - Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis

  NCT06788535· Phase 3· Source

• Terminated

  Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

  NCT05554354· Phase 2· Source

• Completed

  Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers

  NCT06667414· Source

• Recruiting

  A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

  NCT06319820· Phase 3· Source

• Recruiting

  Platform Clinical Study for Conquering Scleroderma

  NCT06195072· Phase 2· Source

• Withdrawn

  Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  NCT06247540· Phase 2· Source

• Completed

  Investigational Extended Wear Insulin Infusion Set in People With Type 1 Diabetes

  NCT06273124· Source

• Completed

  Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

  NCT06169124· Phase 2· Source

• Completed

  SafeHeal Diverting Ileostomy Pivotal Study

  NCT06152276· Source

• Completed

  Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT06058793· Phase 3· Source

• Completed

  An Electronic Health Record-based Approach to Increase PrEP Knowledge and Uptake: the EMC2 PrEP Strategy

  NCT05709860· Source

• Withdrawn

  Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone

  NCT06060587· Phase 2· Source

• Terminated

  Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)

  NCT05744739· Phase 1· Source

• Completed

  Walking Balance Training Post-Stroke

  NCT06090604· Source

• Completed

  Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection

  NCT05776225· Source

• Completed

  A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee

  NCT05931367· Phase 3· Source

• Completed

  A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

  NCT05929066· Phase 3· Source

• Completed

  Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

  NCT05767346· Phase 3· Source

• Withdrawn

  PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer

  NCT04910425· Phase 2· Source

• Completed

  Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis

  NCT05908240· Source

• Completed

  A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes

  NCT05785832· Source

• Completed

  A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

  NCT05882045· Phase 3· Source

• Completed

  Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

  NCT05671835· Phase 2· Source

• Terminated

  ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers

  NCT05616624· Phase 1/2· Source

• Completed

  Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

  NCT05819359· Phase 2· Source

• Completed

  Re-Ablation Using a Tailored Approach Targeting EGM-Dispersion

  NCT05477147· Source

• Completed

  Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate

  NCT05605964· Phase 3· Source

• Completed

  A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).

  NCT05578872· Phase 1/2· Source

• Completed

  A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

  NCT05271604· Phase 2· Source

• Completed

  Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

  NCT05291091· Phase 2· Source

• Recruiting

  Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment

  NCT05363280· Phase 2· Source

• Completed

  Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF

  NCT05284617· Phase 2· Source

• Terminated

  Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory

  NCT05576896· Phase 2· Source

• Completed

  A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX

  NCT05467176· Source

• Completed

  A Novel Measurement Concept to Objectively Quantify Severity of Vocal and Speech Related Symptoms Associated With Parkinson's Disease

  NCT05421832· Source

• Completed

  Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors

  NCT05479812· Phase 1· Source

• Terminated

  Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)

  NCT04871529· Phase 2· Source

• Terminated

  Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer

  NCT05353439· Phase 1· Source

• Withdrawn

  Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer

  NCT05364645· Phase 2· Source

• Completed

  Omnipod 5 System Compared to Pump Therapy

  NCT05409131· Source

• Completed

  Training Swallowing Initiation During Expiration

  NCT05278039· Source

• Completed

  A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma

  NCT05347485· Phase 2· Source

• Completed

  FREEZE-AFIB Post-Market Study

  NCT05089877· Source

Trial sites

• Northwestern University669 trials
• Northwestern University52 trials
• Northwestern University1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Heart failure277 works · 20 trials
• Stroke256 works · 16 trials
• HIV254 works · 9 trials
• Obesity190 works · 14 trials
• Alzheimer disease172 works · 13 trials
• Parkinson disease122 works · 12 trials
• Prostate cancer121 works · 47 trials
• Lung cancer115 works · 75 trials
• Glioblastoma101 works · 14 trials
• Atrial fibrillation100 works · 12 trials
• Asthma96 works · 1 trials
• Atopic dermatitis (eczema)92 works · 4 trials
• Type 2 diabetes87 works · 12 trials
• Epilepsy82 works · 5 trials
• Melanoma74 works · 35 trials
• Chronic kidney disease70 works · 7 trials
• Sarcoma51 works · 28 trials
• Multiple sclerosis40 works · 4 trials
• Psoriasis37 works · 3 trials
• Ovarian cancer36 works · 28 trials
• Ulcerative colitis35 works · 9 trials
• Pancreatic cancer32 works · 28 trials
• Cystic fibrosis32 works · 6 trials
• Coronary artery disease31 works · 7 trials
• COPD31 works · 3 trials
• ALS (motor neurone disease)31 works · 12 trials
• Kidney cancer31 works · 22 trials
• Diabetic eye disease31 works · 1 trials
• Macular degeneration30 works · 0 trials
• Acute myeloid leukemia30 works · 23 trials